David Windley

In a report published Thursday, Jefferies analyst David Windley reiterated a Hold rating on WellCare Health Plans (NYSE: WCG), and raised the price target from $63.00 to $66.00. In the report, Jefferies noted, “WCG's 8% stock surge today (HMOs up 1%) seems an overly strong reaction to a solid,...

In a report published Wednesday, Jefferies analyst David Windley reiterated a Buy rating on UnitedHealth Group (NYSE: UNH), and raised the price target from $71.00 to $78.00. In the report, Jefferies noted, “We expect MCOs to report 2Q earnings upsides. MCO commentary suggests utilization...

In a report published Wednesday, Jefferies analyst David Windley reiterated a Buy rating on Humana (NYSE: HUM), and raised the price target from $95.00 to $98.00. In the report, Jefferies noted, “We expect MCOs to report 2Q earnings upsides. MCO commentary suggests utilization remains favorable...

In a report published Wednesday, Jefferies analyst David Windley reiterated a Hold rating on Cigna (NYSE: CI), and raised the price target from $75.00 to $77.00. In the report, Jefferies noted, “We expect MCOs to report 2Q earnings upsides. MCO commentary suggests utilization remains favorable...

In a report published Wednesday, Jefferies analyst David Windley reiterated a Buy rating on Aetna (NYSE: AET), and raised the price target from $74.00 to $77.00. In the report, Jefferies noted, “We expect MCOs to report 2Q earnings upsides. MCO commentary suggests utilization remains favorable...

In a report published Wednesday, Jefferies analyst David Windley reiterated a Buy rating on WellPoint (NYSE: WLP), and raised the price target from $92.00 to $98.00. In the report, Jefferies noted, “We expect MCOs to report 2Q earnings upsides. MCO commentary suggests utilization remains...

In a report published Thursday, Jefferies analyst David Windley reiterated a Hold rating on PAREXEL (NASDAQ: PRXL), and raised the price target from $41.00 to $43.00. In the report, Jefferies noted, “PRXL's revenue growth will slow markedly over the next year. Reaccelerating in FY15 will...

In a report published Tuesday, Jefferies analyst David Windley reiterated a Hold rating on Centene (NYSE: CNC), and raised the price target from $47.00 to $50.00. In the report, Jefferies noted, “With the future of KY top of mind, management said it still expects to exit the state, likely by...

In a report published Tuesday, Jefferies analyst David Windley initiated coverage on Quintiles Transnational (NYSE: Q) with a Hold rating and $41.00 price target. In the report, Jefferies noted, “The late-stage CRO market is poised to grow 7-9% over the next several years, according to March...

In a report published Thursday, Jefferies analyst David Windley reiterated a Buy rating on Aetna (NYSE: AET), and raised the price target from $69.00 to $74.00. In the report, Jefferies noted, “We are raising our EPS projections to reflect the Coventry acquisition by 5-10c more than accretion...

Jefferies & Company analysts David Windley, Timothy C. Evans and Andrew Hilgenbrink reiterated their Buy rating for shares of Pharmaceutical Product Development Inc (Nasdaq: PPDI), with a price target of $32 per share. The analysts said that Pharmaceutical Product Development Inc management has...

Analysts David Windley and Andrew Hilgenbrink at Jefferies & Company, Inc. have upgraded Warner Chilcott Ltd. (NASDAQ: WCRX) from Hold to Buy rating. The company's management efficient operation continues to drive upsides. As a result, the 2010 guidance looks conservative, according to analysts...

Analyst David Windley at Jefferies & Company, Inc. has maintained a Buy rating for ICON plc (ADR) (NASDAQ: ICLR). Jefferies has maintained its price target of $28.50 for ICON plc. The company has reported results for the fourth-quarter. The company reported EPS of $0.40 on revenue of $227...